Abstract
Introduction
While smoking cessation should be recommended to all patients (1-3), recent reviews have highlighted the importance of smoking in patients with coronary heart disease (CHD) (4) (5) (6) . Smoking cessation is associated with 36-50% reduction in morbidity and mortality in CHD patients, with the benefits of quitting smoking outperforming those related to other preventive strategies such as blood pressure or cholesterol control (2, 3) . Cessation is especially crucial in this population, as continuing to smoke renders such secondary prevention interventions less efficacious (7, 8) , therefore smokers are not deriving the full benefit from preventive therapies. For example, when comparing 4424 treated hypertensives, those who smoked had higher levels of suboptimal diastolic blood pressure 90mmHg or more (33% vs. 25%), along with higher rates of microalbuminuria. Men from the same sample also had higher rates of elevated systolic blood pressure of 140mmHg or more (73% vs. 69%), higher left ventricular hypertrophy, and microalbuminuria, whereas women smokers had higher cholesterol (8) . Similarly, Milionis et al. (7) have demonstrated how smokers in primary and secondary prevention statin trials have failed to glean full benefits from these lipid lowering drugs, with smokers having an extra 23-86% increased risk of a cardiovascular event. While having an acute coronary event can motivate smokers to quit, the majority of smokers continue to smoke or resume smoking within 6 months after such events (6) , therefore identifying factors that predict relapse is of significant value for clinicians.
The prevalence of depression in patients with coronary heart disease (CHD) is elevated in comparison to general population samples (9, 10) . Tobacco use has a longestablished relationship with depression. Those who smoke have a higher incidence of depressive symptoms, and those with depressive symptoms are less likely to quit smoking and are more likely to relapse if they do (4) (5) (6) . For example, secondary analysis of a randomised trial on smoking cessation showed that a greater number of nicotine withdrawal symptoms experienced by depressed smokers, as opposed to nondepressed smokers, mediated the effect of depression on smoking continuation 3-months later. Indeed, this was estimated to account for 27% of the effect of depression on cessation outcomes (11) . It also appears that treating depression in patients with MI may not increase cessation rates (12), and it is unclear whether quitting smoking leads to an improvement in or worsening of depressive symptoms (13).
Therefore, the effect of depression on subsequent cessation may be profound, however, this has not been subject to systematic review or meta-analysis. The American Academy of Family Physicians have described the research on the impact of depression on lifestyle modifications as "low quantity medium to low quality evidence", and they suggest that further investigation is required (14) . Meta-analysis should provide a more precise effect estimate than single studies alone. We quantified the effects of depression on subsequent smoking in patients with CHD. However, as depression is defined in different ways, the potential for misclassification error is high which has the potential to distort estimates of the exposures effect (depression) on the outcome (smoking), thus resulting in biased estimates of the effect of depression.
Similarly, the impact of depressive symptoms may fluctuate over time, or study quality could be heterogeneous. We planned a number of sensitivity analyses to address these potential biases.
Methods
This systematic review with meta-analysis was performed according to recommended principles (15) . 
Study selection and data extraction
Studies were included if they met the following eligibility criteria: CHD samples, published in 1990 or later, prospective, measure of depression at baseline (i.e. diagnostic interview, questionnaire, antidepressant prescription, single-item questions), measure of smoking at follow-up. We included control groups from (non)randomized trials, or combined intervention and control groups from (non)randomized trials (where data for the control groups could not be obtained). We excluded papers which had samples exclusively enrolled in cardiac rehabilitation (CR) programs for two main reasons. Such programs may have intense behavior modification elements, and should have standard measurements of depression and smoking at baseline and outcome.
Thus, a large body of data exists, but is not necessarily reported in each paper on CR.
Furthermore, CR participants are not representative of general CHD patients for many reasons: not all CHD patients are referred to CR; not all referred patients attend CR; those who do attend often drop out; and depression has been shown to predict nonattendance and drop-out, which may bias estimates (16-18). Two reviewers independently completed the first screening of abstracts/titles (DR, AR). Studies that were considered eligible for inclusion were read in full and suitability for inclusion was independently determined by DR and AR. Disagreements were managed by consensus or discussed with a third reviewer (KM or FD). Data were extracted on the basis of study setting, % men, length of follow up, depression measures, smoking status (or relevant results). Authors were contacted to provide further information when there was insufficient data provided in the published paper.
Quality assessment
The quality of the studies was assessed using the Crowe Critical Appraisal Tool (CCAT) 
Results

Study identification
A flow diagram of the search strategy is presented in Figure 1 . The search yielded 1185 papers of which 1165 were excluded. Twenty-eight explored the association between depression and subsequent smoking (11, 12, 25-50). Nine more were omitted (four repeat publications (38, (44) (45) (46) , unavailable data (12, 47, 48, 50), one had too few smokers to provide an estimate (49) -see Appendix A). McGee et al. (37) was treated as two studies, as two depression scales were used in independent groups to predict smoking. This left 20 datasets from 19 articles for analysis.
Characteristics of included studies are displayed in Table 1 , with studies listed in alphabetical order of first author.
----------------- Table 1 here
Study Characteristics
Patients were recruited in hospital settings across 9 countries. Sample sizes at followup ranged from 20-1276. The majority of samples are from patients who presented with acute CHD, with the remainder consisting of two studies including both acute and chronic CHD patients, two studies with CHD outpatients, and one study being unclear (those diagnosed with coronary artery disease after angiography 
Meta-analysis
Using the depression measure hierarchy outlined in the Methods, the forest plot using the best estimate from individual studies is displayed in Fig 2 . 
Sensitivity analyses
Summary estimates for each of the sensitivity analyses are displayed in Table 2 (and Appendix D):
___________ Table 2 here ___________ Estimates were largely unchanged for each of the above conditions. Two studies that used anti-depressants demonstrated an effect size that was between 2-3 times larger than the other estimates (25, 30). One of these studies contributed to significant heterogeneity in the overall estimate and other sensitivity estimates (25), as when it was omitted the overall effect remained similar but the heterogeneity was no longer significant (SMD=-.34, -.42 to -.26, I 2 =21.9%, p=.19). The best estimate from the other study was the depression scale so this was adopted for the other analyses (30).
Discussion
Overall, the results of this review suggest that depression is consistently associated with significantly reduced likelihood of subsequently quitting smoking in CHD patients. This is problematic for CHD patients for two reasons. Firstly, smoking cessation benefits CHD patients. Secondly, smoking continuation has a significant negative impact on therapies that reduce hypertension and cholesterol (7, 8) . Therefore, it is possible that depressive symptoms may be contributing to higher cardiovascular risk in smokers by reducing the probability of cessation.
Size of effect
According to guidelines (24), the effect sizes reported here is 'small' for all analyses except when analysis is confined to studies defining depression using antidepressant prescription. However, even the small estimate is likely to be a clinically significant effect, and for example is of similar magnitude to a reduction in post-MI depression post-intervention (51). That large effects were demonstrated for antidepressant prescription may seem counter-intuitive, as bupropion SR has been shown to increase likelihood of quitting in depressed cardiac patients (11, 52). It is possible that this classification may simply reflect those who have more severe depression and are thus less likely to quit, but more likely to come to clinicians' attention for depression and receive antidepressants. Furthermore, as antidepressants can be prescribed for other problems (pain, other psychiatric conditions, etc.) in those who may not have depression, it is possible that such conditions also affect smoking behavior. Another explanation is that the classification as depressed for those using antidepressants or sedatives in one of these studies (25) may have significantly inflated the depression category, and possibly lead to an overly-large effect size for that study. However, caution should be used when interpreting these sensitivity analyses, as there were very studies in some categories.
Study quality
Any conclusions drawn from such meta-analyses must be cognizant of the quality of the literature reviewed (24). While critical appraisal of primary studies is an essential feature of systematic reviews, the lack of a 'gold standard' appraisal method has been acknowledged (53, 54) with many tools lacking information on development, evaluation of validity or testing reliability (19). Assuming the CCAT ratings were appropriate, this had little effect on our results in sensitivity analyses, and indicates the findings are consistent across studies.
However, other indicators of quality could be considered. Studies largely relied on selfreport data, which could be considered a weakness, despite the fact that such data has excellent sensitivity and specificity for smoking behavior (55) . The severity of smoking addiction, or number of cigarettes smoked were also typically omitted. Possibly more problematic was that studies differed somewhat in their classifications of smokers, or did not report the precise criteria used to categorize smokers and non-smokers.
Furthermore, studies largely did not adjust for other potentially confounding factors when reporting the associations of interest, which means that the present results may be over-estimates. Similarly, the measurement of depression was heterogeneous.
Differential measurement of depression can lead to starkly contrasting results when predicting prognosis (56, 57) . Reassuringly, sensitivity analyses demonstrated similar effect estimates for all measures, with the exception of anti-depressants. It is crucial that future research adopts recommended definitions of smokers (58) , and wherever possible incorporates biochemical measures of smoking, and measures of addiction severity.
Treatments and hospitalization
As depression is typically episodic, and chronic, it is possible that the impact of depression on subsequent smoking fluctuates, with the highest influence during more severe depressive episodes (5). However, sensitivity analysis did not show any major effect of follow-up duration on the present results. Given that nicotine is so addictive (and smoking is typically an everyday activity) any hypothesized fluctuating effects may actually be more important for non-addictive behaviors, such as physical activity.
Furthermore, it is possible that depression may have a stronger effect on smoking initiation than cessation (59) .
While cessation counseling with more than 1-month follow-up has been shown to be effective for cardiac patients (1), and can even reduce post-discharge mortality when combined with pharmacotherapy (60), no randomized trials have assessed smoking interventions in depressed cardiac patients specifically. Available data is limited to posthoc analyses, albeit pre-planned (6, 12) . Similarly, trials have not examined the safety of nicotine replacement therapies (NRT) in acute cardiac patients, and as nicotine has direct effects on the cardiovascular system, RCTs for acute patients are needed to establish safety (6) . These deficiencies in the literature somewhat limit the recommendations that can be made regarding specifically targeting depressed CHD patients who smoke.
In contrast, nicotine replacement therapy (NRT) has been approved for stable CHD patients, and is recommended for selected MI patients as they are being discharged.
NRT acts on withdrawal symptoms, so may be especially important for depressed CHD patients who tend to report higher rates of such symptoms (11). Bupropion SR has been shown to be well-tolerated in patients with acute CVD, and to increase subsequent quit rates in those with elevated depressive symptoms compared to those without (19% v 3%), although this was non-significant (p=.07) probably due to limited sample size (11).
Although varenicline has demonstrated effectiveness in increasing cessation rates in stable cardiac patients, caution is needed when prescribing this therapy in those with depression and CHD, due to reported increases in depressed mood and even suicidality, and intensive monitoring would be required (6) .
Unfortunately, despite hospitalization being a teachable moment for smoking cessation, healthcare professionals advise patients to quit less often than they should (1, 61, 62) .
While the results of the present review suggest that depressed CHD patients may require more intensive intervention, the use of systematic programs on cessation seem to be effective, even when controlling for depression (29, 62). Hospitals should implement such systematic programs, and consider screening for depression in smokers to target those in need of more intensive intervention (6).
Future research
The present findings suggest that further, more sophisticated research is required on the interactions between depression and smoking. Adding multiple follow-up phases with measures of depression and smoking at each phase would provide more detail on the effects of depression over time (4) . While many studies adjust for smoking status at baseline (10), they typically do not account for the number of cigarettes smoked, or whether people quit post event, and therefore the full effects of smoking may not be assessed properly. Such research may also inform the literature on potential behavioral mechanisms linking depression with poorer prognosis in those with coronary heart disease (63, 64), as our results suggest that smoking may be a mediating factor in the depression-prognosis link (65) . As results were largely unadjusted, it is possible that other factors account for the depression-smoking association seen here. Depressed CHD patients have higher cravings, lower confidence in quitting, greater withdrawal symptoms, lower sense of coherence, lower social support than non-depressed smokers (11, 12, 26, 38, 39), and future research should determine the potential interacting effects of these variables. Furthermore, novel therapies such as behavioural activation may need to be investigated, as the efficacy for talk therapies appears to be mixed for depressed patients (4, 12), and our results highlight the need for establishing the best treatments for cessation in depression CHD patients.. Finally, although we studied the association between depression and cessation in CHD patients, future research should establish whether the effects seen here are similar for other populations.
Strengths and Limitations
The results should be interpreted in the context of the limitations relating to the original studies. Although the methodological quality of the included studies was reasonable, eight were rated below the threshold of 60%. However, accounting for quality of the included studies in a sensitivity analysis did not change the pooled effect. In addition, our meta-analysis was restricted to the pooling of unadjusted estimates, thereby failing to account for potential confounders. However, the adjusted estimates did not differ greatly. Furthermore, although we were able to consider the effect of misclassification bias due to different depression measures, we were unable to account for the potential influence of different measures of smoking. However, despite the wide variation in smoking measures, the results across the individual studies are quite consistent as displayed in the forest plot, and when the antidepressant studies are removed, the heterogeneity is no longer significant, thus suggesting the effect is quite robust. There is the possibility that some chance findings are being submitted, or that studies, including those which measure multiple behaviors, are only reporting those with significant associations, and this was supported by some evidence of publication bias. Data were pooled from six different countries, enhancing the generalizability of the findings.
Omission of CR programs also weakens the findings.
Conclusion
Depression reduces the likelihood of quitting smoking in cardiac patients, and this 
